IMPORTANCE Although use of oral anticoagulants (OACs) is increasing, there is a substantial lack of data on how to treat OAC-associated intracerebral hemorrhage (ICH).
coagulopathy, large hematoma volumes and increased rates of hematoma enlargement are characteristics of OACassociated ICH (OAC-ICH) and contribute to an even higher mortality when compared with ischemic stroke or primary ICH. [4] [5] [6] [7] Among all stroke subtypes is a substantial lack of data about how to manage OAC-ICH. 8 Current European Stroke
Organisation guidelines, World Stroke Organization reviews, and American Heart Association Stroke Council recommendations only provide Level C evidence and Class II recommendations regarding treatment of OAC-ICH. 3, 9, 10 Two of the most pressing unsettled questions are how to prevent hematoma enlargement and how to manage anticoagulation in the long-term. 8, 11 Consensus exists that elevated international normalized ratio (INR) levels should be reversed to minimize hematoma enlargement, yet mode, timing, and extent of INR reversal are unclear. 3, 9, 10 Valid data on safety and clinical benefit of OAC resumption are missing and remain to be established.
11
This study investigated (1) the relationship between anticoagulation reversal and blood pressure with hematoma enlargement and (2) the association of restarting anticoagulation with incidence of hemorrhagic and ischemic complications with outcomes among patients with OAC-ICH.
Methods
We chose a retrospective observational study design, and 19 tertiary care centers across Germany participated (7 university hospitals and 12 university-affiliated community hospitals; eFigure 1 in the Supplement). We collected data from all consecutive adult patients with spontaneous ICH (International Statistical Classification of Diseases, Tenth Revision coding: I61.xx) related to anticoagulation admitted to neurological departments between the years 2006 and 2010 with a 1-year follow-up period ending in January 2012. Specifically, the definition of OAC-ICH required effective use of vitamin K antagonists with an INR value of greater than 1.5 on hospital admission. 12 We excluded ICH patients with secondary etiologies, ie, ICH related to trauma, tumor, arteriovenous malformation, aneurysmal subarachnoid hemorrhage, acute thrombolysis, or other coagulopathies. Informed consent was obtained from all patients, legal representatives, or closest relatives. Institutional review boards of all participating centers approved the study based on the central vote from the ethics committee at the University of Erlangen-Nuremberg. The study was titled RETRACE (German-wide Multicenter Analysis of Oral Anticoagulationassociated Intracerebral Hemorrhage) and was conducted on behalf of IGNITE (Initiative of German Neurointensive Trial Engagement). Figure 1 provides an overview of our 3-tiered analyses.
Data Acquisition
We extracted data on demographics, prior comorbidities, inhospital parameters, and laboratory data through review of patients' medical records and institutional prospective databases (see the eMethods in the Supplement for a detailed list of parameters and definitions). Review of medical records and emergency protocols determined neurological status consisting of Glasgow Coma Scale (GCS), National Institutes of Health Stroke Scale (NIHSS), and ICH score. The CHADS 2 and HAS-BLED were scored as appropriate. 13, 14 After the end of the study follow-up, we conducted retrospective data evaluation, which was controlled by repeated visits (≥2) of all participating centers.
We obtained follow-up data on mortality, functional outcome, long-term treatment, and complications by mailed questionnaires and-if not returned or incomplete-by semiquantitative telephone interviews. Two scale-trained physicians, certified for data collection on disability and quality of life, performed the interviews. In situations of missing contact information, a local registry office inquiry was carried out to complete outcome assessment. Cross-checking of centralized data with existing local prospective stroke registries and rehabilitation facility reports ensured data integrity.
Data Synthesis and Analysis

Hematoma Enlargement
We analyzed hematoma enlargement in relation to INR reversal and blood pressure. Hematoma enlargement was defined as a relative parenchymal volume increase of more than 33% from initial to follow-up imaging. 15 We used this conservative threshold, as used in various trials, 16, 17 to exclude falsepositive scoring due to technical variability in computed tomography imaging. 15 We evaluated all available computed tomography and magnetic resonance imaging scans of each patient and calculated parenchymal ICH volume according to hematoma shape, as previously described (ABC/2 and ABC/3).
18,19
When comparing different imaging modalities, we used validated conversion models for precise volume calculation. 20 Intraventricular hemorrhage was recorded and its extent scored by the Graeb score summation.
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We recorded all different agents and dosages used for INR reversal as well as timing and extent of achieved INR levels. Reversal treatment consisted of prothrombin complex concentrates ([PCCs] 4-factor concentrate, containing coagulation factors II, VII, IX, and X as well as protein C and S), 22 
OAC Resumption
Among all patients surviving acute hospitalization, we compared patients who restarted anticoagulation (referred to as OAC resumption) with patients not receiving anticoagulation (referred to as no OAC resumption). Specifically, antithrombotic therapy used exclusively vitamin K antagonists (there was no approval of thrombin and factor Xa inhibitors for stroke prevention in Germany before the end of 2011) or no oral anticoagulants (antiplatelet agents, low-dose heparins, or no pharmacological treatment). For all patients, starting time point (in days) and mode of antithrombotic treatment were recorded. Patients were counted as having resumed OAC at the time of restarted OAC or if they received active heparinization before OAC resumption. Resumption analysis included noting during the 1-year follow-up any new ischemic events, classified as either cerebral (ischemic stroke including transient ischemic attacks) or noncerebral. The latter included peripheral arterial emboli in lungs, gastrointestinal organs, or extremities and myocardial infarction. 23 Recurrent hemorrhagic events were recorded as either cerebral-parenchymal or extracranial bleedings. Extracerebral hemorrhages included gastrointestinal, intraocular, and intramuscular hemorrhage and hematuria. 23 Complications, either ischemic or hemorrhagic, were noted when requiring hospitalization.
Long-term Functional Outcome
Functional outcome was evaluated using the modified Rankin Scale (mRS) at discharge, 3 months (short-term), and 1 year (long-term). We distinguished favorable functional outcome (mRS = 0-3) from unfavorable functional outcome (mRS = 4-6). 24 For analysis of overall mortality, we censored patients who were alive at the end of the study period or recorded cause and time of death. Hematoma enlargement (analysis n = 853) was defined as a relative volume increase >33% on follow-up imaging. Overall, 160 patients received surgical hematoma evacuation; of these, we included 78 patients with follow-up imaging before surgery and excluded 82 patients without follow-up imaging before surgery. Analysis of functional long-term outcome included all the patients in the study (n = 1176). Long-term outcome was assessed at 1 year. Analyses of OAC resumption consisted of graphical displays comparing patients who restarted OAC vs no OAC for ischemic and hemorrhagic events of the entire cohort. Further analyses of OAC resumption were solely based on patients with atrial fibrillation. To minimize confounding by indication, we performed propensity score matching using the balanced, parallel, variable ratio (1:n) nearest-neighbor approach.
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The propensity score was calculated from parameters showing statistical associations (P < .10) with OAC resumption. Propensity-matched survival, displayed using the Kaplan-Meier method, was compared using log-rank, Breslow, and TaroneWare tests. Crude event and incidence rates (per 100 patientyears) for new ischemic and recurrent hemorrhagic strokes were calculated for all individuals and their total number of days receiving target therapy (OAC vs no OAC) until 1-year follow-up. To assess hazard ratios (HRs) for patients who restarted OAC for long-term mortality, we performed unadjusted and adjusted Cox regression analyses for the propensitymatched cohort of patients with atrial fibrillation; variables met assumption of proportionality.
To identify parameters independently associated with functional long-term outcome, we calculated 3 log-binomial regression models: to describe improvement to favorable outcome for patients discharged with mRS of 4 and 5 and to display associations with unfavorable functional outcome for both the unmatched entire cohort as well as for the propensitymatched atrial fibrillation cohort.
For outcome analyses, we considered multiple imputation analyses calculated with all parameters available, ie, baseline characteristics, neurological status, imaging, in-hospital measures, and follow-up measures. Nevertheless, after careful evaluation of missing and auxiliary data for multiple imputation analyses, we decided to conduct complete case analyses for OAC resumption and long-term outcome. 29 For statistical analyses, we used SPSS version 20.0 and R version 2.12.0. Statistical tests were 2-sided, and the significance level was set at α = .05 and consequently corrected for multiple comparisons by the Bonferroni method (eMethods in the Supplement).
Results
Our study cohort consisted of 1176 patients with a complete primary data set. The study cohort was selected from screening of 10 208 consecutive patients with ICH, of whom 1322 patients had OAC-ICH (period prevalence rate of 13.0%). Details about the excluded patients (n = 146) are provided in Figure 1 . We used 2 approaches to identify the "optimal" timing and extent of INR reversal. First, receiver operating characteristics analysis provided an INR value less than 1.3 with the strongest positive association to prevent hematoma enlargement (area under the curve, 0.636; 95% CI, 0.596-0.676; P < .001; 27 The vertical dashed line indicates the last significant OR estimate at 04:12 hours. We only included those patients for analysis (n = 496) for whom the first INR value obtained after initiation of reversal treatment was available within the assessed time frame (00:24-06:36 hours). Error bars indicate 95% CIs.
Complete 1-year follow-up data were available for 719 patients discharged alive. We excluded a total of 93 patients (81 patients had missing follow-up data and 12 withdrew consent) and restricted all outcome analyses to patients with complete data at 1-year follow-up (Figure 1 (Figure 4) .
Atrial fibrillation is the major indication for anticoagulation, clinically of increasing relevance, and patients with atrial fibrillation represented the largest subgroup (n = 566) within our study population. Thus, we based all further analyses of OAC resumption on patients with atrial fibrillation. Within this subgroup, patients who restarted OAC showed a significantly decreased mortality (OAC: 9/110 [8.2%] [5.7%] ; P = .53) (eFigure 2 in the Supplement). Furthermore, we noticed significant differences in baseline characteristics. Specifically, patients who resumed OAC were significantly younger and less severely affected at time of admission and showed superior functional status at time of discharge (eTable 6 in the Supplement).
To minimize confounding, we carried out propensity score matching for factors showing a statistical association with resumption status. The matching resulted in 2 evenly balanced cohorts of patients with atrial fibrillation (range of standardized mean differences, 0.01-0.07) (eTable 7 in the Supplement). When comparing stroke incidence of the matched cohort, we noted a significantly decreased rate of cerebral infarctions (incidence rate per 100 patient-years) for patients who restarted OAC within this matched analysis (OAC: 3.9/ 100 patient-years [95% CI, 1.9-5.8] vs no OAC: 12.7/100 patientyears [95% CI, 6.5-19.1]; P = .02) (eTable 8 in the Supplement). Recurrent ICH occurred without a statistical difference between patients who restarted or did not restart OAC (OAC: 3.9/100 patient-years [95% CI, 1.9-5.8] vs no OAC: 3.9/100 patient-years [95% CI, 2.2-5.7]; P = .92). Mortality analyses of the matched cohort at 1 year showed that 9 of 108 restarted patients (8.3%) vs 47 of 153 patients without OAC (30.7%) had died (P < .001) ( Figure 5 ). This large difference of more than 22% triggered a multivariable-adjusted Cox regression analysis for longterm mortality of the matched atrial fibrillation cohort. Among patients who restarted OAC treatment, there was a significantly decreased HR for long-term mortality of 0.258 (95% CI, 0.125-0.534; P < .001) (eTable 9 in the Supplement).
Long-term Functional Outcome
Investigation of long-term functional outcomes used the entire cohort (n = 1176), and mortality was 364 of 1176 (31.0%) at hospital discharge, 475 of 1102 (43.1%) at 3 months, and 608 of 1083 (56.1%) after 1 year ( Figure 6) . Of all deceased patients during follow-up, 224 of 244 patients (91.8%) were discharged with a functional status of 4 or 5 on the mRS, and of these poor-grade discharged patients, 224 of 511 died (43.8%). Unfavorable functional outcome (mRS = 4-6) was observed in 928 of 1176 patients (78.9%) at time of discharge and decreased to 786 of 1083 patients (72.6%) at 1 year. Hence, the proportion of patients reaching favorable functional outcome increased only by 6.3% during follow-up.
To identify factors in poor-grade survivors (mRS = 4-5) associated with long-term improvement (change to mRS = 0-3), we performed a multivariable analysis and identified the following independent parameters associated with lack of im- Comparing baseline characteristics of patients lost to follow-up with those of patients included for complete case analyses did not show a statistically significant difference regarding all evaluated parameters (eTable 14 in the Supplement). A multiple imputation analysis (eTable 15) resulted in increasing incidences of both ischemic and hemorrhagic complications (introduction of 83 new events: 34 ischemic and 49 hemorrhagic) while mortality and functional outcome would paradoxically decrease at 1-year follow-up. Thus, we conducted complete case analyses to evaluate associations of OAC resumption and long-term outcome.
Discussion
The study represents the largest cohort of patients with OAC-ICH to date and reports 2 clinically valuable associations. First, rates of hematoma enlargement were decreased in patients with INR values reversed below 1.3 within 4 hours of admission and systolic blood pressures of less than 160 mm Hg at 4 hours. Second, rates of ischemic events were decreased among patients who restarted OAC without increased rates of bleeding complications.
The occurrence of hematoma enlargement is an established risk factor for poor outcome in both primary and OACassociated ICH. 6, 17, 24 Pharmacological interventions targeting hemostasis or blood pressure lowering have been shown to prevent hematoma enlargement in primary ICH; however, the effects on clinical end points are uncertain. 16, 32, 33 In OAC-ICH, the pathophysiological mechanism of hematoma enlargement is complex, 8 its occurrence protracted and mainly driven by altered coagulation. 6, 7 This difference from primary ICH constitutes a target for aggressive medical treatment to minimize hematoma enlargement and possibly affect outcome. 6, 7 Although it seems warranted to prospectively investigate the optimal INR reversal and its influence on clinical end points after OAC-ICH, it appears unlikely that sufficiently powered randomized trials will be realized (including a trial of whether PCCs sustain their benefit as an easily available and timely treatment compared with FFP 34, 35 ). The clinical risks and benefits of restarting anticoagulation after OAC-ICH remain intensely debated and were re- Distribution of functional outcome at discharge, 3 months, and 1 year using the modified Rankin Scale (mRS). An mRS of 0 indicates no symptoms; mRS 1, no significant disability, able to carry out all activities prior to stroke, some symptoms; mRS 2, slight disability, unable to carry out all activities prior to stroke, able to look after own affairs; mRS 3, moderate disability, requiring help, walking with cane or walker but without assistance; mRS 4, moderately severe disability, unable to attend bodily needs and to walk without assistance; mRS 5, severe disability, bedridden, requiring constant nursing care and attention; and mRS 6, death.
ICH have an elevated risk for recurrent ICH, 36 which may be increased by restarting OAC. 11 However, our data strengthen previous findings that patients restarting OAC do not show greater risk for recurrent ICH. 30 Based on a considerably high thromboembolic risk without OAC 12,37 (CHADS 2 score ≥2 in 79% of our patients), the increased incidence rate of ischemic stroke observed with our propensity-matched analyses argue in favor of OAC resumption. Only a randomized trial, at least using cluster randomization, will settle the question about which stroke type is clinically more significant: increased rates of ischemic stroke vs lower rates of recurrent, possibly more severe ICH. 11, 12, 30 In this regard, the use of new anticoagulants may further decline risk of recurrent ICH and-given acceptable adherence rates-also the hesitation about resuming anticoagulation 38 counterbalancing self-fulfilling outcome evolutions.
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The present study has several strengths, including a large sample size with 1-year follow-up data from 19 tertiary care centers. Analyses exploited rigorous statistical means to correct for bias and confounding. Nevertheless, some drawbacks limit the interpretation of our findings, the first its retrospective nature, which attenuated data quality. With regards to the determination of hematoma volume and presence of hematoma enlargement, some imprecisions in exact volume assessment remain because the measurements were not computer-assisted. The association of systolic blood pressure with hematoma enlargement may have been influenced by compensatory mechanisms to maintain cerebral perfusion pressure in a subset of patients. 40 Moreover, blood pressure values were not assessed continuously, which left room for uncertainty between the obtained 4-hour intervals.
Comparable with recursive partitioning, our analyses of hematoma enlargement used sequential analyses, leaving room for arbitrariness of used subdivision-related cut points. Hence, this statistical approach may only reflect the characteristics of this study population, which highlights the need for external validation of the reported results by independent populations. With regards to our findings on long-term outcome as well as safety and efficacy of OAC resumption, missing data for patients lost to follow-up potentially biased results. We favored complete-case analyses instead of multiple imputations as comprehensive and meaningful auxiliary may not have been fully assessed (eTable 14 and eTable 15 in the Supplement). Large confidence intervals may reflect certain data instability. We only included ischemic and hemorrhagic events leading to hospitalization and did not longitudinally balance the clinical importance of these events. Although propensity matching minimized confounding by indication, residual bias of parameters not investigated as well as healthy cohort and center effects may not be fully excluded. 28 Finally, long-term follow-up information may have been influenced by erroneously answered questionnaires affecting the validity of mRS estimation.
Conclusions
Among patients with OAC-associated ICH, reversal of INR below 1.3 within 4 hours and systolic blood pressure less than 160 mm Hg at 4 hours were associated with lower rates of hematoma enlargement, and resumption of anticoagulant therapy was associated with lower risk of ischemic events without increased bleeding complications. These retrospective findings require replication and assessment in prospective studies.
